Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22166119 | 0.84 | TSHR (0.34) | TSHRMAPT | |
| SCHEMBL23101917 | 0.80 | HTR2A (0.36) | TSHRPGRCA1CA2 | |
| SCHEMBL12263315 | 0.79 | MET (0.33) | TSHRKDM4E | |
| SCHEMBL23101924 | 0.78 | TSHR (0.31) | TSHR | |
| SCHEMBL24021993 | 0.77 | TSHR (0.33) | TSHRMAPT | |
| SCHEMBL16590512 | 0.77 | TAAR1 (0.40) | TSHRLMNA | |
| SCHEMBL3104509 | 0.76 | PDE2A (0.34) | TSHRKDM4ELMNA | |
| SCHEMBL23046939 | 0.76 | MET (0.31) | — | |
| SCHEMBL10250747 | 0.73 | TSHR (0.40) | TSHRKDM4E | |
| SCHEMBL20354104 | 0.71 | GABRA1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | LIEBER INST INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-10934283-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE, INC. (US) | 2021-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | COMT, PNMT, HNMT | TSHR 4590/4885KDM4E 283/4885LMNA 4431/4885 |
| US-10934283-B2 | COMT inhibiting methods and compositions | COMT, MAOB, MAOA | TSHR 4167/4885KDM4E 1351/4885LMNA 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.